Inhibitors of gut bacterial L-dopa decarboxylation with reduced susceptibility to host metabolism
This study develops difluoroaryl analogs of the gut bacterial L-dopa decarboxylase inhibitor AFMT that effectively block bacterial degradation of levodopa while minimizing unwanted metabolism by host tyrosine hydroxylase, thereby offering a promising strategy for improving Parkinson's disease treatment.